Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Food and Drug Administration drug insert for Campath (alemtuzumab)
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Role of the Blood-Brain Barrier in Multiple Sclerosis.
Gustatory Dysfunction in Multiple Sclerosis
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Ofatumumab Dose-finding in RRMS Patients
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.

Pages